What is a tirzepatide savings card — and how does it work?
A tirzepatide savings card is a manufacturer-sponsored cost-reduction program for branded tirzepatide — marketed as Zepbound for weight management and Mounjaro for blood sugar management in type 2 diabetes. These are two different brand names for the same molecule at similar doses, approved by the FDA through separate regulatory pathways for separate indications.
Savings cards reduce the out-of-pocket cost at the pharmacy counter for eligible commercially insured patients. The manufacturer covers a portion of the cost above a set patient copay — sometimes as low as $25 per fill, sometimes higher depending on the current program terms. These programs are not static: eligibility caps, savings maximums, and program availability change with little notice.
The critical constraint: savings cards are explicitly prohibited from use with Medicare, Medicaid, and other government healthcare programs. If you’re on a federal program, a manufacturer card offers zero benefit. This is not a loophole — it’s enforced.
The real cost of branded tirzepatide without a card
Without insurance coverage or a savings card, you can buy branded tirzepatide direct from Lilly. Through LillyDirect, Zepbound costs $299 a month at 2.5 mg and $399 at 5 mg; 7.5 mg to 15 mg cost $449 when you refill within 45 days, otherwise $499 to $699. Mounjaro starts at $499 a month. A retail pharmacy charging the list price costs more. For patients whose commercial plan excludes GLP-1 weight-management medications, as many plans do, the savings card lowers the single-dose pen to as low as $499 a month.
And that bridge is not guaranteed. Coverage policy battles between employers and insurers over GLP-1 costs are ongoing. Prior authorization requirements, step therapy mandates, and annual formulary changes mean that access through commercial insurance can change from year to year, sometimes mid-year. A savings card does not protect you from a coverage change.
How does compounded tirzepatide compare to the savings card path?
Compounded tirzepatide is a legally distinct option from branded Zepbound or Mounjaro. A clinician has to write for you first, and a licensed 503A compounding pharmacy in the USA then prepares your dose under that prescription. The active ingredient is the same — tirzepatide — but the product is not FDA-approved and has not undergone the same manufacturing review as the branded versions.
The cost difference is meaningful. Compounded tirzepatide through a clinician-supervised program typically costs less per month than Lilly’s self-pay price, and far less than list price. The exact figure depends on starting dose — which is set by the clinician after a review of your health history — and the program structure.
One important detail the savings card doesn’t address: the savings card applies only to the branded product. If you have commercial insurance that covers Zepbound and a valid savings card, you may pay very little monthly. If your insurance doesn’t cover it, the card brings the single-dose pen to as low as $499 a month, or you can pay Lilly’s self-pay price. Compounded tirzepatide pricing is independent of insurance entirely.
| Factor | Branded + savings card | Compounded (503A) |
|---|---|---|
| FDA approval | Yes (Zepbound / Mounjaro) | No — custom-compounded |
| Monthly cost (insured) | As low as $25–$499 with card | Below brand list price; dose-dependent |
| Monthly cost (uninsured / no card) | $299–$699 Zepbound self-pay from Lilly; Mounjaro from $499 | Often below Lilly’s self-pay price; dose-dependent |
| Medicare / Medicaid eligible | Card NOT usable; pay list or coverage rate | Priced independently of insurance status |
| Regulatory durability | Long-term FDA-approved product | Not FDA-approved; compounded per prescription |
| Prescription required | Yes | Yes — clinician evaluation required |
| Sourcing | Branded manufacturer (Eli Lilly) | USA licensed 503A pharmacy |
Quality and sourcing: what to look for
Not all compounded tirzepatide is the same. The 503A pharmacy framework imposes meaningful oversight: pharmacies must operate under state board of pharmacy licensing, comply with USP Chapter 797 sterility standards for sterile preparations, and fill prescriptions for individual patients rather than in bulk for mass distribution.
The risk of gray-market sourcing is real in this space. Online vendors offering tirzepatide without a clinician prescription, without a valid pharmacy license, or through offshore supply chains carry significant risks of contamination, underdosing, or mislabeling. PepScribe works with licensed 503A pharmacies and FDA-registered facilities in the USA — compounded in the USA, no hidden overseas supply chain.
When evaluating any compounded tirzepatide program, ask directly: where is this compounded, what pharmacy license does the facility hold, and does the prescribing clinician have a valid patient-clinician relationship with you? The answer to each question should be specific, not vague.
A savings card chases the brand’s list price; compounded tirzepatide sidesteps insurance entirely — the right choice depends on your coverage, not the coupon.
The regulatory dimension you need to track
Compounded tirzepatide is not an FDA-approved drug product, and that is the piece most cost comparisons leave out. A licensed 503A pharmacy in the USA prepares it for one named patient against a current prescription, and it comes with none of the manufacturer coupons, labeling, or post-market programs that sit behind Zepbound and Mounjaro.
The rules around compounding GLP-1 medicines have moved a good deal in recent years, and FDA has since determined that the tirzepatide injection shortage resolved. The clinician who would prescribe for you is the person to ask what the current record means for your own prescription and your refills, and that is a conversation worth having before price alone decides your path.
If long-term access stability matters more than near-term cost reduction, the branded path with commercial insurance coverage — where applicable — offers more regulatory durability, even at higher out-of-pocket cost.
Which path makes sense?
The honest answer depends on your specific situation. A few questions worth working through with your clinician:
- Do you have commercial insurance that covers GLP-1 weight management? If yes, the savings card route may significantly reduce your cost. If no, you pay list price minus whatever the manufacturer card covers.
- Are you on Medicare or Medicaid? Savings cards won’t help. Compounded tirzepatide through a clinician-supervised program is priced independently of insurance, which is why it is worth pricing out.
- How important is regulatory certainty? Branded tirzepatide is an FDA-approved product with a settled regulatory pathway. Compounded tirzepatide is not FDA-approved, and each fill depends on a current prescription written for you.
- Are you starting from scratch or already on a dose? Switching from branded to compounded (or vice versa) mid-protocol introduces variables a clinician should manage, not something to do opportunistically based on price alone.
Tirzepatide is a clinically meaningful tool for weight management when prescribed and monitored appropriately. Cost access matters, but it should be evaluated alongside the sourcing quality, regulatory status, and ongoing clinical oversight of whatever path you choose.
Frequently asked questions
What is a tirzepatide savings card?
A tirzepatide savings card is a manufacturer-issued coupon that reduces out-of-pocket cost for branded tirzepatide (Zepbound or Mounjaro) for commercially insured patients. The cards do not apply to Medicare, Medicaid, or other government programs. Eligibility requirements and savings limits vary by program and can change.
How much does branded tirzepatide cost with a savings card?
With Lilly's savings card, commercially insured patients whose plan covers Zepbound or Mounjaro may pay as little as $25 a month, and those whose plan does not cover it as low as $499 for the single-dose pens. Without insurance, Lilly sells Zepbound direct through LillyDirect for $299 to $699 a month depending on dose ($449 at 7.5 mg and up when you refill within 45 days) and Mounjaro from $499. Actual out-of-pocket depends heavily on your specific insurance plan.
Can I get a tirzepatide savings card if I have Medicare?
No. Manufacturer savings cards are explicitly excluded from use with Medicare, Medicaid, and other federal healthcare programs by law. Patients on government coverage need to evaluate other cost-reduction strategies with their clinician or pharmacist.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
Compounded tirzepatide is not the same product as Zepbound or Mounjaro. Compounded preparations are made by licensed 503A pharmacies and FDA-registered facilities under a clinician's prescription. Compounded tirzepatide is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or consistency. The brand products have undergone full FDA review; compounded preparations have not.
How much does compounded tirzepatide cost?
Compounded tirzepatide through clinician-supervised programs typically runs lower than Lilly's self-pay price for Zepbound and well below brand list price. Exact pricing depends on the dose, the pharmacy, and the program structure. A consult-first model allows the clinician to recommend the appropriate starting dose, which directly affects cost.
Is compounded tirzepatide legal?
Compounded tirzepatide is not an FDA-approved drug product. Section 503A of the Federal Food, Drug, and Cosmetic Act addresses a pharmacy preparing a medication for one named patient who holds a valid prescription, and that is how a PepScribe patient receives it: a licensed clinician reviews your health history and writes the prescription, then a licensed 503A pharmacy in the USA prepares it. The preparation itself is a tirzepatide and cyanocobalamin combination, dosed for the individual. Your prescribing clinician can tell you what would be in the vial you receive and how refills are handled.




